Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings

Introduction Harms due to methamphetamine use disorder (MAUD) are rising globally. Untreated withdrawal symptoms perpetuate the cycle of dependence and are a barrier to treatment. There is no pharmacotherapy approved for methamphetamine withdrawal. Lisdexamfetamine (LDX) dimesylate has potential as...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Dan I Lubman, Jonathan Brett, Andrew Carr, Paul S Haber, Adrian J Dunlop, Nicholas Lintzeris, Frances R Levin, Nadine Ezard, Rebecca McKetin, Brendan Clifford, Michael Doyle, Krista J Siefried, Nathan Taylor, Michael Christmass, Steven Shoptaw, Shalini Arunogiri, Liam S Acheson, Mark Donoghoe, Jack Nagle
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2025-11-01
Seri Bilgileri:	BMJ Open
Online Erişim:	https://bmjopen.bmj.com/content/15/11/e107242.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings

Benzer Materyaller